Portal de Periódicos da CAPES

Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months

2019; Elsevier BV; Volume: 158; Linguagem: Inglês

10.1016/j.diabres.2019.107916

1872-8227

Fernando Moreno Obregón, José Pablo Miramontes‐González, Catalina Romo Guajardo-Fajardo, Ángel Luis Muñoz Nieto, J. López-Suárez, Javier Martín‐Vallejo, Yolanda Arco-Prados, María Dolores García de Lucas, David León Jiménez,

Peptidase Inhibition and Analysis

Dulaglutide is an agonist of "glucagon-like peptide type 1″ receptors (arGLP1). The clinical efficacy of this molecule is based on reductions in glycosylated hemoglobin (HbA1c) and weight, data shown in the pivotal AWARD studies.We propose a retrospective and multicenter study that allows evaluating the effectiveness of dulaglutide at 24 months after treatment began, under conditions of usual clinical practice, and comparing the results obtained with those that are reflected in the controlled trials.The results show a reduction in the HbA1c levels -1.4% at 6 M and this reduction were maintained throughout 12 M and 24 M (p < 0.001). Plasma glucose showed significant reductions around -30 mg / dL at 6 months (p < 0.001) that remained until the end of the follow-up at 12 and 24 M, respectively. The weight decreased significantly at 6 M (p < 0.001) but continued decreasing at 12 and 24 M, showing statistically significant differences (p: 0.001).Our results are similar to those obtained in pivotal clinical trials and confirm these benefits in real life.